Key result
Warfarin is linked to higher bleeding and costs versus apixaban in elderly VTE patients.
Why the study?
Does apixaban reduce bleeding risk and healthcare costs compared to warfarin in elderly patients with venous thromboembolism?
Does apixaban reduce bleeding risk and healthcare costs compared to warfarin in elderly patients with venous thromboembolism?
In elderly Medicare patients with VTE, apixaban is associated with lower bleeding risks and healthcare costs compared to warfarin, while maintaining similar effectiveness against recurrent VTE.
Answers are grounded in this paper and cite their sources.
May favor apixaban over warfarin to reduce bleeding and costs in elderly VTE; leaves open need for randomized confirmation.
Warfarin was associated with significantly higher risk of MB and CRNM bleeding as well as higher MB-related and all-cause costs vs apixaban patients. Recurrent VTE risk and costs were similar among warfarin and apixaban patients.
No takes yet. Share an insight, caveat, or question.
Hlavacek et al. (2019) studied this question. Warfarin was associated with significantly higher major and clinically relevant non-major bleeding risks and costs versus apixaban in elderly VTE patients, with similar recurrent VTE risk.
Synapse has enriched 10 related papers. Consider them for comparative context: